These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 31564556)

  • 1. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.
    Fornaro L; Leone F; Vienot A; Casadei-Gardini A; Vivaldi C; Lièvre A; Lombardi P; De Luca E; Vernerey D; Sperti E; Musettini G; Satolli MA; Edeline J; Spadi R; Neuzillet C; Falcone A; Pasquini G; Clerico M; Passardi A; Buscaglia P; Meurisse A; Aglietta M; Brac C; Vasile E; Montagnani F
    Clin Colorectal Cancer; 2019 Dec; 18(4):e394-e401. PubMed ID: 31564556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
    Shibuki T; Mizuta T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Taguchi H; Honda T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T; Otsuka T
    BMC Cancer; 2022 Jan; 22(1):19. PubMed ID: 34980029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms.
    Brada LJH; Walma MS; Daamen LA; van Roessel S; van Dam RM; de Hingh IH; Liem MLS; de Meijer VE; Patijn GA; Festen S; Stommel MWJ; Bosscha K; Polée MB; Yung Nio C; Wessels FJ; de Vries JJJ; van Lienden KP; Bruijnen RC; Los M; Mohammad NH; Wilmink HW; Busch OR; Besselink MG; Quintus Molenaar I; van Santvoort HC;
    J Surg Oncol; 2021 Sep; 124(4):589-597. PubMed ID: 34115379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Important Radiologic and Clinical Factors for Predicting Overall Survival in Pancreatic Adenocarcinoma Patients Who Underwent FOLFIRINOX.
    Park SJ; Kim JH; Choi SY; Joo I
    Pancreas; 2024 Aug; 53(7):e553-e559. PubMed ID: 38530942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
    Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
    Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.
    Suker M; Nuyttens JJ; Groot Koerkamp B; Eskens FALM; van Eijck CHJ
    J Surg Oncol; 2018 Nov; 118(6):1021-1026. PubMed ID: 30259526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
    Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
    Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison.
    van Veldhuisen E; Vroomen LG; Ruarus AH; Derksen TC; Busch OR; de Jong MC; Kazemier G; Puijk RS; Sorgedrager NS; Vogel JA; Scheffer HJ; van Lienden KP; Wilmink JW; Besselink MG; Meijerink MR
    J Vasc Interv Radiol; 2020 Oct; 31(10):1600-1608. PubMed ID: 32861569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
    Zahir MN; Jabbar AA
    Asian Pac J Cancer Prev; 2015; 16(14):6001-6. PubMed ID: 26320487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
    Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
    Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
    Bonnet E; Mastier C; Lardy-Cléaud A; Rochefort P; Sarabi M; Guibert P; Cattey-Javouhey A; Desseigne F; de La Fouchardière C
    Curr Oncol; 2019 Aug; 26(4):e466-e472. PubMed ID: 31548814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
    Lee HS; Kim SY; Chung MJ; Park JY; Bang S; Park SW; Song SY
    Nutr Cancer; 2019; 71(7):1100-1107. PubMed ID: 30955349
    [No Abstract]   [Full Text] [Related]  

  • 14. Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.
    Kamposioras K; Papaxoinis G; Dawood M; Appleyard J; Collinson F; Lamarca A; Ahmad U; Hubner RA; Wright F; Pihlak R; Damyanova I; Razzaq B; Valle JW; McNamara MG; Anthoney A
    Acta Oncol; 2022 May; 61(5):583-590. PubMed ID: 35392758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
    Vienot A; Beinse G; Louvet C; de Mestier L; Meurisse A; Fein F; Heyd B; Cleau D; d'Engremont C; Dupont-Gossart AC; Lakkis Z; Tournigand C; Bouché O; Rousseau B; Neuzillet C; Bonnetain F; Borg C; Vernerey D
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28383673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.
    Boisteau E; Dahan L; Williet N; Le Malicot K; Desramé J; Bouché O; Petorin C; Malka D; Rebischung C; Aparicio T; Lecaille C; Rinaldi Y; Turpin A; Bignon AL; Bachet JB; Lepage C; Granger V; Legoux JL; Deplanque G; Baconnier M; Lecomte T; Bonnet I; Seitz JF; François E; Lièvre A;
    Oncologist; 2024 Sep; 29(9):e1149-e1158. PubMed ID: 39235326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-matched Analysis.
    Brada LJH; Daamen LA; Magermans LG; Walma MS; Latifi D; van Dam RM; de Hingh IH; Liem MSL; de Meijer VE; Patijn GA; Festen S; Stommel MWJ; Bosscha K; Polée MB; Nio YC; Wessels FJ; de Vries JJJ; van Lienden KP; Bruijnen RC; Busch OR; Koerkamp BG; van Eijck C; Molenaar QI; Wilmink HJW; van Santvoort HC; Besselink MG;
    Ann Surg; 2021 Nov; 274(5):729-735. PubMed ID: 34334641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second-line palliative chemotherapy.
    Hsu CC; Liu KH; Chang PH; Chen PT; Hung CY; Hsueh SW; Yeh KY; Chen YY; Lu CH; Hung YS; Chou WC
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1694-1703. PubMed ID: 31711261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer.
    Lee W; Oh M; Kim JS; Sung M; Hong K; Kwak BJ; Park Y; Jun E; Song KB; Hwang DW; Lee JH; Yoo C; Kim KP; Park I; Jeong JH; Chang HM; Ryoo BY; Lee JB; Kim SC
    Int J Surg; 2024 Jul; 110(7):4074-4082. PubMed ID: 38537071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
    Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
    Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.